Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
APPROVED_FOR_MARKETING
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease
NCT00074932
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease
NCT00074919
High Dose or High Dose Frequency Study of Alglucosidase Alfa
NCT00483379
Late-Onset Treatment Study Extension Protocol
NCT00455195
A Study of rhGAA in Patients With Late-Onset Pompe Disease
NCT00250939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])
IV infusion: 20mg/kg qow
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must reside in the US.
* The patient must have a confirmed diagnosis of Pompe disease defined as documented acid alpha-glucosidase (GAA) enzyme deficiency from any tissue source and/or GAA gene mutations.
* The patient must have/had documented clinical signs and symptoms of Pompe disease.
* The patient must have/had prior treatment with alglucosidase alfa produced at commercial scale OR be naive to enzyme replacement therapy (ERT) for the treatment of Pompe disease and meet at least 1 of the following criteria: require a wheelchair OR require some respiratory assistance for any number of hours (including night time) through non-invasive ventilation.
* The patient must be capable of complying with the required program schedule of assessments.
Exclusion Criteria
* The patient has a clinical condition unrelated to Pompe disease that would interfere with program assessments.
* The patient is currently enrolled in any clinical studies.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genzyme, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Genzyme, a Sanofi Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sheffield, Alabama, United States
Anchorage, Alaska, United States
Phoenix, Arizona, United States
Prescott, Arizona, United States
Scottsdale, Arizona, United States
Tucson, Arizona, United States
Bakersfield, California, United States
Beverly Hills, California, United States
Loma Linda, California, United States
Los Angeles, California, United States
Sacramento, California, United States
San Diego, California, United States
Stanford, California, United States
Aurora, Colorado, United States
Washington D.C., District of Columbia, United States
Bradenton, Florida, United States
Coral Springs, Florida, United States
Daytona Beach, Florida, United States
Gainsville, Florida, United States
St. Petersburg, Florida, United States
Decatur, Georgia, United States
Boise, Idaho, United States
Chicago, Illinois, United States
Evansville, Indiana, United States
Iowa City, Iowa, United States
Kansas City, Kansas, United States
Louisville, Kentucky, United States
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
Augusta, Maine, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Springfield, Massachusetts, United States
Detroit, Michigan, United States
Grand Rapids, Michigan, United States
Lake Orion, Michigan, United States
Rochester Hills, Michigan, United States
Saint Joseph, Michigan, United States
Minneapolis, Minnesota, United States
Missoula, Montana, United States
Omaha, Nebraska, United States
Midland Park, New Jersey, United States
Albuquerque, New Mexico, United States
Albany, New York, United States
Corning, New York, United States
Manhasset, New York, United States
New York, New York, United States
Asheville, North Carolina, United States
Durham, North Carolina, United States
Jacksonville, North Carolina, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Greenville, Ohio, United States
Toledo, Ohio, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Greenville, South Carolina, United States
West Colombia, South Carolina, United States
Houston, Texas, United States
San Antonio, Texas, United States
Waco, Texas, United States
Salt Lake City, Utah, United States
Charlottesville, Virginia, United States
Chesapeake, Virginia, United States
Newport News, Virginia, United States
Richmond, Virginia, United States
Winchester, Virginia, United States
Pullman, Washington, United States
Seattle, Washington, United States
Morgantown, West Virginia, United States
Green Bay, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AGLU03907
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.